银屑病真实世界研究:依奇珠单抗与司库奇尤单抗两年治疗依从性比较
该研究基于IBM MarketScan理赔数据库,比较了成人斑块状银屑病患者使用依奇珠单抗(471例)或司库奇尤单抗(990例)后24个月的治疗模式。结果显示,与司库奇尤单抗相比,依奇珠单抗使用者的非持续性风险降低20%、停药风险降低17%,高依从性 odds 提高42%,但切换风险无显著差异。
要点
- 依奇珠单抗较司库奇尤单抗24个月非持续性风险降低20%(HR 0.80)。
- 依奇珠单抗停药风险降低17%(HR 0.83),高依从性 odds 提高42%(OR 1.42)。
- 两药切换风险无显著差异(HR 0.83,95%CI 0.68-1.01)。
核心结论
- 在真实世界24个月观察中,依奇珠单抗使用者较司库奇尤单抗使用者表现出更好的持续性和依从性,且停药风险更低。
研究设计与样本
- 共纳入471例依奇珠单抗使用者和990例司库奇尤单抗使用者,采用逆概率治疗加权和多变量模型平衡队列。
主要发现
- 依奇珠单抗组非持续性风险较司库奇尤单抗组降低20%(HR 0.80,95%CI 0.70-0.92)。
- 依奇珠单抗组停药风险降低17%(HR 0.83,95%CI 0.72-0.96)。
- 依奇珠单抗组高依从性(覆盖天数比例≥80%)的 odds 提高42%(OR 1.42,95%CI 1.12-1.80)。
- 两组切换风险无显著差异(HR 0.83,95%CI 0.68-1.01)。
临床怎么用
- 在真实世界选择IL-17A抑制剂时,可参考依奇珠单抗较司库奇尤单抗在24个月内具有更好持续性和依从性的证据。
局限性
- 研究缺乏疾病严重程度和临床结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Real-world data on long-term treatment patterns associated with interleukin-17A inhibitors in plaque psoriasis are lacking. OBJECTIVE: To compare ixekizumab or secukinumab treatment patterns over a 24-month period among plaque psoriasis patients. METHODS: Adult patients with psoriasis who had 1 or more claims for ixekizumab or secukinumab between March 1, 2016, and October 31, 2019, and with 24 months of follow-up after starting treatment were identified from IBM MarketScan claims databases. Inverse probability of treatment weighting and multivariable models were employed to balance cohorts and estimate the risks of nonpersistence, discontinuation, and switching and odds of highly adherent treatment (proportion of days covered ≥ 80%). RESULTS: A total of 471 ixekizumab and 990 secukinumab users were included. Compared to secukinumab, ixekizumab use was associated with a 20% lower risk of nonpersistence (hazard ratio, 0.80; 95% CI, 0.70-0.92), a 17% lower risk of discontinuation (hazard ratio, 0.83; 95% CI, 0.72-0.96), and a 42% higher odds of being highly adherent to treatment (odds ratio, 1.42; 95% CI, 1.12-1.80). No difference in risk of switching was observed (hazard ratio, 0.83; 95% CI, 0.68-1.01). LIMITATIONS: Disease severity and clinical outcomes were unavailable. CONCLUSION: Over 24 months, ixekizumab users exhibited better persistence and adherence, and a lower risk of discontinuation than secukinumab users in real-world settings.
引用
- Blauvelt A, Shi N, Somani N, et al. Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings. J Am Acad Dermatol. 2021. PMID: 34252464. doi:10.1016/j.jaad.2021.06.878
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。